0001104659-24-065806.txt : 20240529 0001104659-24-065806.hdr.sgml : 20240529 20240529070913 ACCESSION NUMBER: 0001104659-24-065806 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240529 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240529 DATE AS OF CHANGE: 20240529 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Milestone Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001408443 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38899 FILM NUMBER: 24993997 BUSINESS ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 BUSINESS PHONE: (514) 336-0444 MAIL ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 8-K 1 tm2415708d1_8k.htm FORM 8-K
false 0001408443 A8 00-0000000 QC 0001408443 2024-05-29 2024-05-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

May 29, 2024

 

 

 

MILESTONE PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

 

 

Québec   001-38899   Not applicable
(state or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

1111 Dr. Frederik-Philips Boulevard,    
Suite 420    
Montréal, Québec CA   H4M 2X6
(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (514) 336-0444

 

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Shares   MIST   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 8.01. Other Events.

 

On May 29, 2024, Milestone Pharmaceuticals Inc. (“Milestone” or the “Company”) issued a press release announcing that its resubmitted New Drug Application for CARDAMYST (etripamil) nasal spray, its lead investigational product for the management of paroxysmal supraventricular tachycardia, has been accepted for filing by the U.S. Food and Drug Administration and that the Prescription Drug User Fee Act target date is 10 months from the acceptance date of May 26, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No. Description
99.1 Press release, dated May 29, 2024.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MILESTONE PHARMACEUTICALS INC.
   
Date: May 29, 2024 By: /s/ Amit Hasija
    Amit Hasija
    Chief Financial Officer Principal Financial Officer

 

 

 EX-99.1 2 tm2415708d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

 

Montreal and Charlotte, N.C., May, 29, 2024 -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the United States Food and Drug Administration (FDA) accepted the Company’s New Drug Application (NDA) on May 26, 2024 for CARDAMYST (etripamil) nasal spray, its lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT). The FDA Prescription Drug User Fee Act (PDUFA) target date is 10 months from the acceptance date of May 26, 2024.

 

“The FDA’s acceptance of our NDA for CARDAMYST brings Milestone one step closer in our mission in providing a new, convenient and effective treatment option for patients with PSVT,” said Joseph Oliveto, President, and Chief Executive Officer of Milestone Pharmaceuticals. “We understand the frequent impact that PSVT has on patients, as well as the underappreciated burden it places on their families and caregivers. Our progress toward providing a sense of security for patients is a result of the dedicated Milestone team, patients, and investigators to whom we are thankful.”

 

The CARDAMYST clinical trial program represents the largest data package ever studied for an acute drug treatment intended for patient self-management of PSVT events. Milestone continues to advance commercial preparations to support the anticipated launch of etripamil with the proposed trade name, CARDAMYST. The brand name is conditionally approved by the FDA.

 

About Paroxysmal Supraventricular Tachycardia

 

An estimated two million people in the United States are currently diagnosed with PSVT which is a type of arrhythmia or abnormal heart rhythm. PSVT is characterized by episodes of sudden onset rapid heartbeats often exceeding 150 to 200 beats per minute. The heart rate spike is unpredictable and may last several hours. The rapid heart rate often causes disabling severe palpitations, shortness of breath, chest discomfort, dizziness or lightheadedness, and distress, forcing patients to limit their daily activities. The uncertainty of when an episode of PSVT will strike or how long it will persist can provoke anxiety in patients and negatively impact their day-to-day life between episodes. The impact and morbidity from an attack can be especially detrimental in patients with underlying cardiovascular or medical conditions, such as heart failure, obstructive coronary disease, or dehydration. Many health care providers are dissatisfied with the lack of effective treatment options with patients often requiring prolonged, burdensome, and costly trips to the emergency department or even invasive cardiac ablation procedures.

 

 

 

 

 

 

About CARDAMYST (etripamil) nasal spray

 

CARDAMYST is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid response therapy for patients thereby bypassing the need for immediate medical oversight. If approved, etripamil is intended to provide health care providers with a new treatment option to enable on-demand care and patient self-management. This portable, self-administered treatment may provide patients with active management and a greater sense of control over their condition. The clinical trial program for CARDAMYST includes a completed Phase 3 clinical-stage program for the treatment of PSVT and Phase 2 trial for the treatment of patients with AFib-RVR.

 

About Milestone Pharmaceuticals

 

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is CARDAMYST (etripamil) nasal spray, a novel calcium channel blocker that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "continue," "could," "demonstrate," "designed," "develop," "estimate," "expect," "may," "pending," "plan," "potential," "progress," "will", “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding our ability to bring a new PSVT therapeutic option to market; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies, including the FDA; the timing of the launch of etripamil; and our ability to advance commercial preparations to support the anticipated launch of etripamil. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether our future interactions with the FDA will have satisfactory outcomes; the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 10-K for the year ended December 31, 2023, under the caption "Risk Factors," as such discussion may be updated from time to time by subsequent filings Milestone may make with the U.S. Securities & Exchange Commission. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

 

 

 

 

 

 

Contact:

 

Kim Fox, Vice President, Communications, kfox@milestonepharma.com

 

Investor Relations

 

Chris Calabrese, ccalabrese@lifesciadvisors.com

Kevin Gardner, kgardner@lifesciadvisors.com

 

 

 

 EX-101.SCH 3 mist-20240529.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mist-20240529_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mist-20240529_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2415708d1_ex99-1img001.jpg GRAPHIC begin 644 tm2415708d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 29, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 29, 2024
Entity File Number 001-38899
Entity Registrant Name MILESTONE PHARMACEUTICALS INC.
Entity Central Index Key 0001408443
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code A8
Entity Address, Address Line One 1111 Dr. Frederik-Philips Boulevard
Entity Address, Address Line Two Suite 420
Entity Address, City or Town Montréal
Entity Address, State or Province QC
Entity Address, Country CA
Entity Address, Postal Zip Code H4M 2X6
City Area Code 514
Local Phone Number 336-0444
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares
Trading Symbol MIST
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://milestonepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, dei:EntityIncorporationStateCountryCode - tm2415708d1_8k.htm 21, 23 mist-20240529.xsd mist-20240529_lab.xml mist-20240529_pre.xml tm2415708d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2415708d1_8k.htm": { "nsprefix": "mist", "nsuri": "http://milestonepharma.com/20240529", "dts": { "schema": { "local": [ "mist-20240529.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "mist-20240529_lab.xml" ] }, "presentationLink": { "local": [ "mist-20240529_pre.xml" ] }, "inline": { "local": [ "tm2415708d1_8k.htm" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://milestonepharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2415708d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2415708d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001104659-24-065806-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-065806-xbrl.zip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tm2415708d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001408443 2024-05-29 2024-05-29 iso4217:USD shares iso4217:USD shares false 0001408443 A8 00-0000000 QC 8-K 2024-05-29 MILESTONE PHARMACEUTICALS INC. 001-38899 1111 Dr. Frederik-Philips Boulevard Suite 420 Montréal CA H4M 2X6 514 336-0444 false false false false Common Shares MIST NASDAQ true true